Relationship between autonomic function and plasma fibrinogen, viscosity, and elements of fibrinolytic activity in diabetic nephropathy

American Journal of Hypertension

Volumn 10, Issue 4 I, 1997, Pages 454-461

  Weinrauch, Larry A ^a,c,d,e   Gleason, Ray E ^b,e   Keough, Joanne ^d   D'Elia, John A ^a,d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

autonomic function; insulin dependent diabetes mellitus; plasma fibrinogen

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FIBRINOLYSIS; HEART RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; PROTEINURIA; UREMIA; VALSALVA MANEUVER; VISCOSITY;

ADULT; AGED; AUTONOMIC NERVOUS SYSTEM; BLOOD VISCOSITY; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED;

EID: 0030897518     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00448-7     Document Type: Article

References (33)

1. Sheps SG, Pickering TG, White WB, et al: ACC Position Statement. Ambulatory blood pressure monitoring, J Am Coll Cardiol 1994;23:1511-1513.
2. Dreifus LS, Agarwal JB, Botvinick EH, et al: ACC Position Statement. Heart rate variability for risk stratification of life threatening arrhythmias. J Am Coll Cardiol 1993;22:948-950.
3. Vaishanav S, Stevenson R, Marchant B, et al: Relation between heart rate variability early after myocardial infarction and long-term mortality. Am J Cardiol 1994; 73:653-657.
4. van Ravenswaaij CMA, Kollee LAA, Hopman JCW, et al: Heart rate variability. Ann Intern Med 1993;118: 435-447.
5. Bellavere F, Bosello G,; Cardone C, et al: Evidence of early impairment of parasympathetic reflexes in insulin dependent diabetics without autonomic symptoms. Diabete et Metabolisme 1985;11:152-156.
6. Ewing D, Campbell I, Clarke B: Heart rate changes in diabetes mellitus. Lancet 1981;i:183-184.
7. Weinrauch L, Kennedy F, Gleason RE, et al: Autonomic function in type 1 diabetes mellitus complicated by nephropathy - a cross-sectional analysis in the presymptomatic phase. Am J Hypertens 1995;8:782-789.
8. Muller JE, Tofler GH: Circadian variation and cardiovascular disease. N Engl J Med 1991;325:1038-1039.
9. Tofler GH, Gebara OCE, Mittleman MA, et al, for the CPI Investigators: Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. Circulation 1995;92: 1203-1208.
10. Bernardi L, Ricordi L, Lazzari P, et al: Impaired circadian modulation of sympathovagal activity in diabetes: a possible explanation for altered temporal onset of cardiovascular disease. Circulation 1992;86:1443-1452.
11. Dougherty CM, Burr RI: Comparison of heart rate variability in survivors and non survivors of sudden cardiac arrest. Am J Cardiol 1992;70:441-448.
12. Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-Infarction Research Group: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
13. Peters RW, Muiler JE, Goldstein S, et al: Propranolol and the morning increase in frequency of sudden cardiac death (BHAT study). Am J Cardiol 1989;63:1518-1520.
14. Middlekauff HR, Sontz EM: Morning sympathetic nerve activity is not increased in humans: implications for mechanisms underlying the circadian pattern of cardiac risk. Circulation 1995;91:2549-2555.
15. MacIsaac AI, Thomas JD, Topol EJ: Toward the quiescent coronary plaque. J Am Coll Cardiol 1993;22:1228-1241.
16. Muller JE, Tofler GH, Verrier RL: Sympathetic activity as the cause of the morning increase in cardiac events a likely culprit but the evidence remains circumstantial. Circulation 1995;91:2508-2509.
17. Weinrauch LA, D'Elia JA, Healy RE, et al: Asymptomatic coronary artery disease: assessment in diabetics evaluated for renal transplantation. Circulation 1978; 58:1184-1190.
18. Manske CL, Thomas W, Wang Y, Wilson RF: Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup. Kidney Int 1993;44:617-621.
19. Braun WE, Phillips DF, Vidt DG, et al: Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc 1984;16:603-607.
20. Philipson JD, Carpenter BJ, Itzkoff J, et al: Evaluation of cardiovascular risk for renal transplantation in diabetic patients. Am J Med 1986;81:630-634.
21. Aoki TT, Benbarka M, Okimura MC, et al: Long-term intermittent intravenous insulin therapy and type 1 diabetes. Lancet 1993;432:515-518.
22. SAS Institute Inc.: SAS User's Guide: Statistics, Version ed. Cary, NC, SAS Institute Inc., 1985, pp 529-557.
23. Winocur PD, Watala C, Kinglough-Rathbone RL: Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ration in isolated platelet membranes from diabetic and control subjects Thromb Hemost 1992;67:567-571.
24. Schmidt AM, Yan SD, Stern DM: The dark side of glucose. Nature Med 1995;1:1002-1004.
25. Morise T, Takeuchi Y, Kawano M, et alP: Increased plasma levels of immunoreactive endothelin and von Wiliebrand factor in NIDDM patients. Diabetes Care 1995;8:87-89.
26. Lin J, Duh E, Jiang Z: Expression of preproendothelin1 mRNA in streptozotocin-induced diabetic rats (abst). Diabetes 1996;45:48A.
27. Ambrose JA, Weinrauch M: Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382-1394.
28. Verghese M, Hasdai D, Lerman A: The role of endothelin in coronary atherosclerosis. Mayo Clinic Proceedings 1996;71:769-777.
29. Bird JE, Moreland S, Waldron TL, Pewell JR: Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 1995;25:1191-1195
30. Jones RL, Peterson CM: Reduced fibrinogen survival in diabetes mellitus. J Clin Invest 1979;63:485-493.
31. The Diabetes Control and Complications Research Group: The effects of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engi J Med 1993;342:515-518.
32. Hamstein A, Waldius G, Szamosi A, et al: Plasminogen activator inhibitor in plasma: risk for recurrent myocardial infarction. Lancet 1987;ii:3-8.
33. Prins MH, Hirsh J: A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991;122:545-551.